- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Cleveland Clinic | Strategic Alliance Partners
Cleveland Clinic Cancer Institute provides complete cancer care enhanced by innovative basic, clinical and translational research. It offers the most effective techniques to achieve long-term survival and improve patients’ quality of life. Cleveland Clinic Cancer Institute’s more than 800 physicians, researchers, nurses and technicians care for thousands of patients each year and provide access to a wide range of clinical trials. Cleveland Clinic Cancer Institute has a global presence, uniting clinicians based in our Cancer Institute, Cleveland Clinic’s other patient-centered institutes, our regional hospitals and health centers, and our operations in Florida, London and Abu Dhabi. Cleveland Clinic is a nonprofit, multi-specialty academic medical center with more than 5,000 staff physicians and researchers who integrate outpatient and hospital care with research and education for better patient outcomes and experience. Cleveland Clinic is a trusted healthcare leader. We’re recognized in the U.S. and throughout the world for our expertise and care.
Be sure to tune into our Cancer Advances podcast where we explore the latest innovative research and clinical advances in the field of oncology. Listen now!
Connect with us:
Latest from Cleveland Clinic
Expanding JAK Inhibitor Arsenal Provides Additional Options Beyond Ruxolitinib in Myelofibrosis
December 16, 2024
Article
Aaron Gerds, MD, discusses differences in molecular targets, efficacy, and toxicity profiles between available JAK inhibitors in myelofibrosis.
Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer
December 12, 2024
Video
Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.
Sharing the Latest in Breast Cancer Care With Drs Rena Callahan and Jame Abraham
December 11, 2024
Video
Jame Abraham, MD, of Cleveland Clinic, and Rena D. Callahan, MD, of UCLA, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.
Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies
December 09, 2024
Article
Second-generation BTK inhibitors were associated with a significantly lower incidence of cardiac adverse effects in B-cell malignancies.
Targeted Therapies Remain Central to Ongoing Research in Pancreatic Cancer
November 30, 2024
Article
Suneel Kamath, MD, shares insights on targeted therapies in pancreatic cancer after an X Takeover with OncLive during Pancreatic Cancer Awareness Month.
Dr Kamath on the Rise in Incidence of Pancreatic Cancer
November 27, 2024
Video
Suneel Kamath, MD, discusses the rising incidence of pancreatic cancer during Pancreatic Cancer Awareness Month.
Dr Truong on the Background of the ImmunoCobiVem Trial in BRAF V600+ Melanoma
November 07, 2024
Video
Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial of early switch from targeted therapy to immunotherapy in advanced BRAF V600–positive melanoma.
Navigating Myelofibrosis: Updates for Community Hematologist Oncologists
October 14, 2024
Podcast
Drs Gerds and McCloskey discuss JAK inhibitors for patients with myelofibrosis, tips for symptom management, and emerging myelofibrosis research.
Dr Truong on Targeted Therapy vs Immunotherapy in BRAF V600–Positive Melanoma
October 07, 2024
Video
Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial investigating the switch from targeted therapy to immunotherapy in advanced BRAF V600+ melanoma.
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
September 11, 2024
Podcast
Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.
Dr Ornstein on the Use of IO/TKI Doublets in Non-ccRCC
September 06, 2024
Video
Moshe Ornstein, MD, MA, discusses the use of first-line IO/TKI doublet regimens in patients with non–clear cell renal cell carcinoma.
Pelabresib/Ruxolitinib Data Underscore Need for Novel End Points in Myelofibrosis Trials
July 15, 2024
Article
Aaron Gerds, MD discusses updated efficacy findings from the prospective randomized phase 3 MANIFEST-2 trial.
Dr Winter on Unmet Needs in Richter Transformation for Patients With CLL
June 24, 2024
Video
Allison Winter, MD, discusses unmet needs for patients with Richter transformation from CLL.
Dr Yilmaz on HB-200 Arenavirus Plus Pembrolizumab in HPV16+ Head and Neck Cancer
June 21, 2024
Video
Emrullah Yilmaz, MD, PhD, discusses HB-200 arenavirus–based immunotherapy plus pembrolizumab in recurrent/metastatic HPV16+ head and neck cancer.
Dr Winter on Real-World Outcomes With Liso-Cel in Richter Transformation
June 20, 2024
Video
Allison Winter, MD, discusses data from a retrospective analysis evaluating real-world outcomes with liso-cel in patients with Richter transformation.
Dr Gerds on the Clinical Implications of Pelabresib Plus Ruxolitinib in Myelofibrosis
June 14, 2024
Video
Aaron Gerds, MD, discusses the clinical implications of outcomes with pelabresib plus ruxolitinib therapy in JAK inhibitor–naive myelofibrosis.
Dr Kamath on the Rationale for Investigating Early-Onset vs Average-Onset PDAC
June 12, 2024
Video
Suneel Kamath, MD, discusses the rationale for conducting an investigation into the tumor microbiome differences between early- and average-onset PDAC.
Dr Kamath on the Tumor Microbiome of Early- and Average-Onset PDAC
June 10, 2024
Video
Suneel Kamath, MD, discusses tumor microbiome differences between early-onset and average-onset pancreatic adenocarcinoma.
Dr Carraway on the Importance of NGS in Relapsed/Refractory AML
May 29, 2024
Video
Hetty E. Carraway, MD, MBA, discusses the importance of testing for targetable mutations in patients with relapsed/refractory acute myeloid leukemia.
Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
May 24, 2024
Article
James Ignatz-Hoover, MD, PhD, discusses the evolving use of CAR T-cell therapies and bispecific antibodies in multiple myeloma.